Gilead Sciences, Inc. (NASDAQ:GILD) plans to ask FDA to approve arthritis drug this year
Gilead Sciences, Inc. (NASDAQ:GILD)announced afternoon that it plans to ask the Food and Drug Administration to approve an arthritis drug this year. Gilead, in partnership with Galapagos NV GLPG, has been testing a drug known as filgotinib for rheumatoid arthritis, and the latest study results excited investors in March. In a news release Monday, Gilead said that it met with the FDA to discuss those test results recently. “As a result of this discussion, a path forward has been established to submit the NDA for filgotinib as a treatment for rheumatoid arthritis in 2019,” the release said.
insider ownership percentage is the key indicator, can be used by investors, to
measure the outlook of senior management has on their company. Insider
ownership for the GILD is 0.30%. Institutional ownership refers to the
ownership stake in a company that is held by large financial organizations, pension
funds or endowments. The Institutional ownership for the GILD is 82.50%.
Insider trading is the buying or selling of any publicly traded company’s stock and this can be done by someone who has non-public, material information about that GILD. Insider trading can be illegal or legal depending on when the insider makes the trade. It is illegal when the material information is still non-public. The insider transactions of the company (6-month change in insider ownerships) for the Gilead Sciences, Inc. (NASDAQ:GILD) is -1.62%.
Institutional ownership is the amount of a Gilead Sciences, Inc. (NASDAQ:GILD)’s available stock owned by mutual or pension funds, insurance companies, investment firms, private foundations, endowments or other large entities that actually manage the funds on the behalf of others, so its an interesting element for the traders to note it, and the Institutional ownership for the GILD is -0.43%.
a Healthcare sector firm, Gilead Sciences, Inc.
(NASDAQ:GILD) stock advanced 0.40% on Monday and when day-trade ended the stock
finally concluded at $67.83 and number of shares that changed hands during the
day are 6.01 Million. The number of shares GILD stock currently held by all its
shareholders are 1276.00 and floated shares, the number of shares are available
for trading in an open market on last trading day are 1264.69. The average
volume of shares for 3 months is 6761.51 and GILD stock value has moved between
$60.56 – 79.8 in last one year.
The Gilead Sciences, Inc. (NASDAQ:GILD)’s latest earnings date is 8/1/2019. The Gross margin is the difference between the revenue and the cost of goods sold (COGS), divided by revenue. In other words, Gross Margin is a percentage value, while Gross Profit is a monetary value. The valuable gross margin for Gilead Sciences, Inc. (NASDAQ:GILD) is 78.50% and the profit margin is 26.40% and the stock has gained 8.44% in 2019 to date.
U.S. traded shares of Gilead Sciences, Inc. (NASDAQ:GILD)’s monthly stock performance is 8.96%, the quarterly performance is 2.96%, the half year performance is calculated as 9.62%. The yearly performance of GILD is -3.55%.
The higher the volatility, the riskier the security. For example, when the stock market rises and falls more than one percent over a sustained period of time, it is called a “volatile” market, if the stock price stays relatively stable, the security has low volatility. The Gilead Sciences, Inc. (NASDAQ:GILD) weekly volatility is measured as 2.29% and monthly volatility measured as 2.01%.
Return on assets (ROA) is a main indicator of how profitable a company is relative to its total assets. GILD return on assets is 9.20%, the return on equity (ROE) of the Gilead Sciences, Inc. (NASDAQ:GILD) is 26.80%, while the most important return on investment is calculates as a percentage and is typically used for personal financial decisions, and GILD return on investment is 12.00%.
The price to earnings ratio is 14.95, price to sales ratio is 3.88, and price to book ratio is 3.94, price to cash per share ration is 3.10, price to free cash flow is 24.11.
Analysts mean target price for Gilead Sciences, Inc. (NASDAQ:GILD) is $79.54 while analysts mean recommendation is 2.10. The current share price indicates that stock is -14.80% away from its one year high and is moving 12.45% ahead of its 52-week low. GILD’s distance from 20 day simple moving average is 1.70% and distance from 50-Day simple moving average is 3.22%.